Abstract
This paper describes a proposed mechanism of boron accumulation to and release from melanoma after administration of p-Boronophenylalanine (p-BPA) to melanoma patients. The study is based on chemical experiments modeling the phenomena occurring in melanoma cells. Before the mechanism study, we would like to mention the history of the BNCT compound, p-BPA.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
A. H. Soloway, R. L. Wright, and J. R. Messer, Evaluation of boron compounds for use in neutron capture therapy of brain tumors. 1. Animal investigations. J. Pharniacol. Exp. Ther, 134: 117–122, 1961.
Y. Mishima, Neutron capture treatment of malignant melanoma using 1°B-chlorpromazine compound. in: “Pigment Cell. Vol. 1:Mechanisms in pigmentation ”, V. J. Mc. Govern and P. Russell eds., S. Karger, Basel, 1973, pp. 215–221.
K. Yoshino, H. Kakihana, M. Okamoto, and Y. Mori, Chemical behavior of Dopaborate and10B-p-Boronophenylalanine. in: “Neutron Capture Therapy” H. Hatanaka. ed., Nishimura Co., Ltd., Niigata, Japan, 1986, pp. 55–60.
H. Kakihana, M. Okamoto and K. Yoshino, Chemical problems in neutron capture therapy. Kyoto Univ. Research Reactor Inst. Technical Report - 195: 115–120, 1980. (in Japanese)
Y. Mishima, M. Ichihashi, T. Nakanishi, T. Nakagawa, Selective neutron capture therapy of cancer cells using their specific functional differentiation. -with special reference to malignant melanoma- Kyoto Univ. Research Reactor Inst. Technical Report - 195: 3–18, 1980.
M. Ichihashi, T. Nakanishi, and Y. Mishima, Specific killing effect of 10B1-para-boronophenylalanine in thermal neutron capture therapy of malignant melanoma: in vitro radiobiological evaluation. J. Invest. Dermatol., 78: 215–218, 1982.
K. Yoshino, M. Okamoto, H. Kakihana, Y. Mori, Y. Mishima, M. Ichihashi, M. Tsuji, and T. Nakanishi, Chemical assay of boron and its distribution in melanoma-bearing subjects. in: “Neutron Capture Therapy ”, H. Hatanaka ed., Nishimura Co. Ltd., Niigata, Japan, 1986, pp. 291–302.
Y. Mishima, M. Ichihashi, T. Nakanishi, M. Tsuji, M. Ueda, T. Nakagawa, and T. Suzuki, Cure of malignant melanoma by single thermal neutron capture treatment using melanoma seeking compounds; 10B/melanogenesis interaction to in vitro/in vivo radiobiological analysis to preclinical studies. in: Proc. 1st Int. Symp. Neutron Capture Therapy, R. G. Fairchild, G. L. Brownell eds. BNL51730. BNL, Upton, N.Y. 1984, pp. 355–364.
Y. Mishima, M. Ichihashi, S. Hatta, C. Honda, K. Yamamura, T. Nakagawa, H. Obara, J. Shirakawa, J. Hiratsuka, K. Taniyama, C. Tanaka, K. Kanda, T. Kobayashi, T. Sato, M. R. Ishida, Y. Ujeno, M. Takahashi, M. Abe, T. Nozaki, O. Aizawa, T. Matsumoto, T. Sato, H. Karashima, K. Yoshino, and H. Fukuda, First human clinical trial of melanoma neutron capture. Diagnosis and therapy. Strahlenther Onkol. 165: 251–254, 1989.
K. Yoshino, A. Suzuki, Y. Mori, H. Kakihana, C. Honda, Y. Mishima, T. Kobayashi, and K. Kanda, Improvement of solubility of p-Boronophenylalanine by complex formation with monosaccharides. Strahlenther. Onkol. 165: 127–129, 1989.
Y. Mori, A. Suzuki, K. Yoshino, and H. Kakihana, Complex formation of p-Boronophenylalanine with some monosaccharides. Pigment Cell Research 2: 273–277, 1989.
Y. Kinoshita, K. Yoshino, Y. Mori, H. Kakihana, and Y. Mishima, Complex formation of phenylboronic acid derivatives with alodopentoses and oligosaccharides. in: “Progress in Neutron Capture Therapy for Cancer”, B. J. Allen et al. eds., Plenum Press, New York, 1992, pp. 243–246.
H. Kakihana, K.. Yoshino, and Y. Mori, Relation between structures of p-Boronophenylalanine related compounds and their usefulness for boron neutron capture therapy. in: “Advances in Neutron Capture Therapy”, A. H. Soloway et al. eds., Plenum Press, New York, 1993, pp. 257–260.
C. Honda, M. Shiono, N. Wadabayashi, S. Hatta, M. Ichihashi, Y. Mishima, K. Yoshino, T. Kobayashi, K. Kanda, and Y. Hori, 1081-BPA administration to human melanoma patients: boron analytical studies for neutron capture therapy. Kyoto Univ. Res. Reactor Inst. Technical Report - 357: 7–18, 1991.
H. Fukuda, BNCT of malignant melanoma - Radiobiological analysis and data comparison with conventional radiotherapy. “Cancer Neutron Capture Therapy”, Y. Mishima ed., Plenum Press, New York, Proc. 6th Intnl. Symp. on Neutron Capture Therapy for Cancer, Oct. 31 - Nov. 4, 1994, Kobe Japan.
S. Ueda, Y. Imahori, Y. Ohmori, K. Ono, T. Kobayashi, M. Takagaki, Y. Oda, T. Ido, and Y Mishima, Positron emission tomography and boron neutron capture therapy system to a patient with brain tumor. “Cancer Neutron Capture Therapy”, Y. Mishima ed., Plenum Press, New York, Proc. 6th Intnl. Symp. on Neutron Capture Therapy for Cancer, Oct. 31 - Nov. 4, 1994, Kobe Japan.
J. A. Coderre, BNCT for malignant glioma using BPA: Radiation biology and treatment planning. “Cancer Neutron Capture Therapy”, Y. Mishima ed., Plenum Press, New York, Proc. 6th Intnl. Symp. on Neutron Capture Therapy for Cancer, Oct. 31 - Nov. 4, 1994, Kobe Japan.
J. A. Coderre, J. D. Glass, R. G. Fairchild, U. Roy, S. Cohen, and I. Fand. Selective targeting of boronophenylalanine to melanoma in BALB/c mice for neutron capture therapy. Cancer Res. 47: 6377–6383, 1987.
C. Honda, M. Shiono, N. Wadabayashi, M. Ichihashi, Y. Mishima, K. Yoshino, T. Kobayashi, K. Kanda, Y. Hori, and H. Karashima, Increased boron uptake by hamster melanoma using L-isomer10B1-BPA for neutron capture therapy. Kyoto Univ. Res. Reactor Inst. Technical Report - 356: 243–248, 1991.
J. A. Coderre, J. D. Glass, R. G. Fairchild, P. L. Micca, I. Fand, and D. D. Joel, Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma. Cancer Res. 50: 138–141, 1990.
Y. Mishima, A post melanoma era: Control of melanogenesis and melanoma growth. Pigment Cell Research Suppl. 2: 3–16, 1992.
M. Shiono, T. Shibata, M. Ichihashi, Y. Mishima, The mechanism of the selective affinity of 10B1 -paraboronophenylalanine for malignant melanoma.. J. Kobe Univ. School of Medicine 53 (1): 35–41, 1992.
We have confirmed by the UV spectroscopic method.
C. Honda, M. Shiono, N. Wadabayashi, M. Ichihashi, Y. Mishima, T. Kobayashi, K. Kanda, Y. Hori, and K. Yoshino, Increased selective 11B-uptake by malignant melanoma using systematic administration of 10B1 -BPA-fructose complex. in: “Progress in Neutron Capture Therapy for Cancer”. B. J. Allen et al. eds., Plenum Press, New York, 1992, pp. 421–424.
H. Fukuda, J. Hiratsuka, C. Honda, T. Kobayashi, K. Yoshino, H. Karashima, J. Takahashi, Y. Abe, K.. Kanda, M. Ichihashi, and Y. Mishima, Boron neutron capture therapy of malignant melanoma using 10B-paraboronophenylalanine with special reference to evaluation of radiation dose and damage to the normal skin. Radiation Research 138: 435–442, 1994.
K. Yoshino, T. Maruyama, Y. Mori, H. Kakihana, and Y. Mishima, Capture ofp-Boronophenylalanine by melanin-related compounds: Complex formation of p-Boronophenylalanine with L-DOPA. in: “Advances in Neutron Capture Therapy”, A. H. Soloway et al. eds., Plenum Press, New York, 1993, pp. 249–252.
K. Yoshino, H. Kakihana, and Y. Mori, N. Torii, H. Takahashi, and Y. Mishima, Proposed mechanism of capture and release ofp-Boronophenylalanine in melanoma cells: chemical behavior ofp-Boronophenylalanine-fructose complex in L-dopa solution. in: “Advances in Neutron Capture Therapy”, A. H. Soloway et al. eds., Plenum Press, New York, 1993, pp. 253–256.
E. M. Rinchik, S. J. Bultman, B. Horsthemike, S. T. Lee, K. M. Strunk, R. A. Sparitz, K. M. Avidano, M. T. C. Jong, and R. D. Nicholls, A gene for the mouse pink-eyed dilution locus and lbr human type II oculocutaneous albinism. Nature, 361: 72–76. 7 January 1993.
K. T. Yasunobu and E. R. Norris, Mechanism of borate inhibition of diphenol oxidation by tyrosinase..1. Biol. Chem. 227:473–482, 19.57.
K. Yoshino, H. Takahashi, N, Torii, Y. Mori, and H. Kakihana, Complex formation of p-Boronophenylalanine with melanin precursor, Dopa, and its oxidation. Kyoto Univ. Res. Reactor Inst. Technical Report–382: 33–38, 1993. (in Japanese).
Y. Mishima, Molecular and biological control of melanogenesis through tyrosinase genes and intrinsic and extrinsic regulatory factors, Pigment Cell Res. 7: 376–387, 1994.
A. Wilczek and Y. Mishima, Regulatory factors for polymerization of melanin monomers within coated vesicles and premelanosomes in melanoma cells. Melanoma Res., 3: 255–262, 1993.
S. Hatta, Y. Mishima, M. Ichihashi, and S. Ito, Melanin monomers within coated vesicles and premelanosomes in melanin synthesizing cells.. 1. Invest. Dermatol., 91: 181–184, 1988.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Yoshino, K., Mori, Y., Kakihana, H., Takahashi, H., Mishima, Y., Ichihashi, M. (1996). Chemical Modeling with p-Boronophenylalanine for Boron Accumulation to and Release from Melanoma. In: Mishima, Y. (eds) Cancer Neutron Capture Therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9567-7_9
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9567-7_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9569-1
Online ISBN: 978-1-4757-9567-7
eBook Packages: Springer Book Archive